Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

NCT05779644 · Unknown status

Last updated 2026-05-28

This clinical trial tests the effects of a GLP-1 receptor agonist (GLP-1RA) on blood sugar levels, weight, metabolism, and fat distribution in adults who are overweight or obese and have type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 300 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2023-02 · est. completion 2025-02

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05779644 ↗

Description as written by the study sponsor.

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

Treatments tested

Liraglutide Drug

Liraglutide is injected once a day.
Semaglutide Drug

Semaglutide is injected once a week.
Metformin Drug

Metformin is taken orally daily.

Main thing measured	Blood glucose
Sponsor	RenJi Hospital
Conditions studied	Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat, Non-Alcoholic Fatty Liver Disease, Metabolism Disorder, Glucose, Metabolism Disorder, Lipid
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05779644 ↗